IP Verse

Methods Of Treating Lennox-Gastaut Syndrome Using Fenfluramine - EP3340971

The patent EP3340971 was granted to Zogenix on Mar 13, 2024. The application was originally filed on Aug 24, 2016 under application number EP16840062A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3340971

ZOGENIX
Application Number
EP16840062A
Filing Date
Aug 24, 2016
Status
Granted And Under Opposition
Feb 9, 2024
Grant Date
Mar 13, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

KRAUS & LEDERER PARTGMBBNov 19, 2024KRAUS & LEDERER PARTGMBBADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2006270611
INTERNATIONAL-SEARCH-REPORTUS2011092535
INTERNATIONAL-SEARCH-REPORTUS2011212171
INTERNATIONAL-SEARCH-REPORTUS2014343162
INTERNATIONAL-SEARCH-REPORTWO2014177676
OPPOSITIONUS2016092652
OPPOSITIONWO2015026849

Non-Patent Literature (NPL) Citations (9) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "Dexfenfluramine containing medicinal products with Marketing Authorisation in the European Union ", ANNEX I LIST OF THE NAMES OF THE MEDICINAL PRODUCTS, MARKETING AUTHORISATION HOLDERS, PHARMACEUTICAL FORMS, STRENGTHS, ROUTE OF ADMINISTRATION, PACKAGING AND PACKAGE SIZES IN THE MEMBER STATES, European Medicines Agency, (20000101), pages 1 - 15, ANNEX I LIST OF THE NAMES OF THE MEDICINAL PRODUCTS, MARKETING AUTHORISATION HOLDERS, PHARMACEUTICAL FORMS, STRENGTHS, ROUTE OF ADMINISTRATION, PACKAGING AND PACKAGE SIZES IN THE MEMBER STATES , URL: https://ec.europa.eu/health/documents/community-register/2000/200003093428/anx_3428_en.pdf, XP093239172-
OPPOSITION- D8 - SUBMISSION OF PATENTEE, DATED FEBRUARY 15, 2023-
OPPOSITION- Ku Leuven, "NCT02655198 Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy (FFA-LGS)", ClinicalTrials.gov, NLM, (20160816), pages 1 - 10, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT02655198?tab=history&a=3#version-content-panel, XP093239159-
OPPOSITION- Béla Clemens, "Dopamine agonist treatment of self-induced pattern-sensitive epilepsy. a case report", Epilepsy Research, Elsevier Science publishers , Amsterdam, NL, NL , (19880901), vol. 2, no. 5, doi:10.1016/0920-1211(88)90044-7, ISSN 0920-1211, pages 340 - 343, XP055566425
OPPOSITION- Mudigoudar Basanagoud; Weatherspoon Sarah; Wheless James W., "Emerging Antiepileptic Drugs for Severe Pediatric Epilepsies", SEMINARS IN PEDIATRIC NEUROLOGY, SAUNDERS, PHILADELPHIA, PA, US, US , (20160604), vol. 23, no. 2, doi:10.1016/j.spen.2016.06.003, ISSN 1071-9091, pages 167 - 179, XP029689530
OPPOSITION- Schoonjans An-Sofie, Lieven Lagae, Berten Ceulemans, "Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome", Therapeutic Advances in Neurological Disorders, Sage Publications Ltd., United Kingdom, United Kingdom , (20150101), vol. 8, no. 6, doi:10.1177/1756285615607726, ISSN 1756-2856, pages 328 - 338, XP055566569
SEARCH- HENRI GASTAUT ET AL, "Compulsive respiratory stereotypies in children with autistic features: Polygraphic recording and treatment with fenfluramine", JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, US, (19870901), vol. 17, no. 3, doi:10.1007/BF01487068, ISSN 0162-3257, pages 391 - 406, XP055507540 [X] 1-2,4,7 * abstract * * page 399 * [Y] 1-11
SEARCH- B�LA CLEMENS, "Dopamine agonist treatment of self-induced pattern-sensitive epilepsy. a case report", EPILEPSY RESEARCH., NL, (19880901), vol. 2, no. 5, doi:10.1016/0920-1211(88)90044-7, ISSN 0920-1211, pages 340 - 343, XP055566425 [X] 1-2,4,7-8,10 * the whole document * [Y] 1-11
SEARCH- YIFAN ZHANG ET AL, "Pharmacological Characterization of an Antisense Knockdown Zebrafish Model of Dravet Syndrome: Inhibition of Epileptic Seizures by the Serotonin Agonist Fenfluramine", PLOS ONE, (20150512), vol. 10, no. 5, doi:10.1371/journal.pone.0125898, page e0125898, XP055507508 [Y] 4-7 * abstract * * page 16 - page 17 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents